ZIOPHARM Oncology Inc

Most Recent

  • uploads///AdobeStock_

    Will Genocea Stock Bounce Back? In-Depth Analysis

    Today, we’re taking a close look at Genocea (GNCA) to show why the stock could bounce back after fluctuating significantly over the last year.

    By Oleksandr Pylypenko
  • uploads///cell therapy
    Company & Industry Overviews

    Cell Therapy Market Could Boost Celgene’s Long-Term Growth

    With the acquisition of Juno Therapeutics, Celgene will benefit from all of Juno Therapeutics’ facilities related to cell therapy.

    By Daniel Collins
  • uploads///Celgene Strategy
    Company & Industry Overviews

    Behind Celgene’s Strategy in the Juno Therapeutics Acquisition

    With the acquisition of Juno Therapeutics (JUNO), Celgene (CELG) will likely become an established cellular immunotherapy company.

    By Daniel Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    How Did Ziopharm Keep XBI from Losing More Ground?

    Year-to-date, Ziopharm has a return of -12.5%. Ziopharm has a book value of $0.72. With its current price, the stock is trading at a PBV ratio of 10.1x.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Arena Rose 14% in XBI’s Small-Cap Space

    Arena Pharmaceuticals (ARNA) rose 14% on November 2, 2015. The stock went up on high trading volumes with ~4.7 million shares being traded.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.